5. Beyer WJ, Lensing AW, Arya R, et al. Choosing wisely: the impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.Thromb Res, 2017, 149: 29-37.
[4]
6. Weekes AJ, Thacker G, Troha D, et al. Diagnostic accuracy of right ventricular dysfunction markers in normotensive emergency department patients with acute pulmonary embolism. Ann Emerg Med, 2016, 68(3): 277-291.
[5]
8. Zhao DJ, Ma DQ, He W, et al. Cardiovascular parameters to assess the severity of acute pulmonary embolism with computed tomography.Acta Radio, 2010, 51(4): 413-419.
[6]
10. Meinel FG, Nance JW, Schoepf UJ, et al. Predictive value of computed tomography in acute pulmonary embolism: systematic review and Meta-analysis.Am J Med, 2015, 128(7): 747-759.
[7]
11. Trujillo-Santos J, den Exter PL, Gómez V, et al. Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis.J Thromb Haemost, 2013, 11(10): 1823-1832.
[8]
12. Keller K, Beule J, Schulz A, et al. Right ventricular dysfunction in hemodynamically stable patients with actue pulmonary embolism.Thromb Res, 2014, 133(4): 555-559.
[9]
13. Kreit JW.The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism.Chest, 2004, 125: 1539-1545.
[10]
14. Cho JH, Kutti Sridharan G, Kim SH. Right ventricular dysfunction as an echocardiographic prognostic factor in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. BMC Cardiovasc Disord, 2014, doi: 10.1186/1471-2261-14-64.
[11]
15. Bing R, Chow V, Lau JK, et al. Prevalence of echocardiography use in patients hospitalized with confirmed acute pulmonary embolism: a real-world observational multicenter study.Plos One, 2016, 11(12): e0168554.
[12]
16. Celik Y, Yardan T, Baydin A, et al. The role of NT-proBNP and Apelin in the assessment of right ventricular dysfunction in acute pulmonary embolism.J Pak Med Assoc, 2016, 66(3): 306-311.
[13]
17. Lankeit M, Jiménez D, Kostrubiec M, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism.Eur Respir J, 2014, 43(6): 1669-1677.
[14]
18. Bircan A, Karadeniz N, Ozden A, et al. A simple clinical model composed of ECG, shock index, and arterial blood gas analysis for predicting severe pulmonary embolism.Clin Appl Thromb Hemost, 2011;17(2): 188-196.
[15]
2. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidlines on the diagnosis and management of actue pulmonary embolism.Kardio Pol, 2014, 72(11): 997-1053.
[16]
4. Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012, 366 (14): 1287-1297.
[17]
7. Park JR, Chang SA, Jang SY, et al. Evaluation of right ventricular dysfunction and prediction of clinical outcomes in acute pulmonary embolism by chest computed tomography: comparisons with echocardiography.Int J Cardiovasc Imaging, 2012, 28(4): 979-987.
[18]
9. Jimenez D, Lobo JL, Monreal M, et al. Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study.Thorax, 2014, 69(2): 109-115.
[19]
19. Ince O, Altintas N, Findik S, et al. Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient.Hippokratia, 2014, 18(4): 333-339.
[20]
20. Ozsu S, Abul Y, Yilmaz I, et al. Prognostic significance of PaO2/PaCO2 ratio in normotensive patients with pulmonary embolism.Clin Respir J, 2012, 6(2): 104-111.
